- Home
- NDLS vs KPTI Comparison
NDLS vs KPTI Comparison
Compare NDLS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- KPTI
- Stock Information
- Founded
- NDLS 1995
- KPTI 2008
- Country
- NDLS United States
- KPTI United States
- Employees
- NDLS N/A
- KPTI N/A
- Industry
- NDLS Restaurants
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- KPTI Health Care
- Exchange
- NDLS Nasdaq
- KPTI Nasdaq
- Market Cap
- NDLS 45.2M
- KPTI 54.4M
- IPO Year
- NDLS 2013
- KPTI 2013
- Fundamental
- Price
- NDLS $0.90
- KPTI $6.10
- Analyst Decision
- NDLS Strong Buy
- KPTI Strong Buy
- Analyst Count
- NDLS 2
- KPTI 5
- Target Price
- NDLS $3.00
- KPTI $61.00
- AVG Volume (30 Days)
- NDLS 79.4K
- KPTI 84.2K
- Earning Date
- NDLS 05-07-2025
- KPTI 05-20-2025
- Dividend Yield
- NDLS N/A
- KPTI N/A
- EPS Growth
- NDLS N/A
- KPTI N/A
- EPS
- NDLS N/A
- KPTI N/A
- Revenue
- NDLS $495,670,000.00
- KPTI $145,237,000.00
- Revenue This Year
- NDLS $4.57
- KPTI $4.87
- Revenue Next Year
- NDLS $1.29
- KPTI $16.29
- P/E Ratio
- NDLS N/A
- KPTI N/A
- Revenue Growth
- NDLS N/A
- KPTI N/A
- 52 Week Low
- NDLS $0.55
- KPTI $3.51
- 52 Week High
- NDLS $2.36
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- NDLS 38.19
- KPTI 55.45
- Support Level
- NDLS $0.81
- KPTI $5.90
- Resistance Level
- NDLS $1.09
- KPTI $7.90
- Average True Range (ATR)
- NDLS 0.07
- KPTI 0.66
- MACD
- NDLS 0.00
- KPTI 0.07
- Stochastic Oscillator
- NDLS 21.07
- KPTI 40.29
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.